Glibenclamide (glyburide) is widely used in the treatment of several forms of diabetes [16,17], because it binds to the sulphonylurea receptors, which associate with the ATP-sensitive K+ channels of beta cells, thus stimulating insulin release [1]. This evidence concerns the gene INS and diabetes mellitus.